Close Menu
September 16, 2020
Sponsored by
Agilent

Development of a Wastewater Analysis Protocol for SARS-CoV-2 Using Quantitative Real-Time PCR

GenomeWebinar

Technical Director,
Weck Laboratories

Product Manager, PCR and qPCR Reagents,
Agilent Technologies

Surveillance analysis of potentially pathogenic microbes found in shared public resources is an important component of research aimed at understanding, preparing for, and protecting communities from potential widespread infection and transmission of infectious diseases. For example, wastewater testing for SARS-CoV-2 has emerged as an efficient, cost-effective, and reliable method for assessing and estimating population infection levels. This approach may provide data to develop predictive modeling tools, enabling hospital and ICU occupancy trend analysis in the future. 

The fastest and most affordable method to date for quantitative viral detection is the quantitative reverse transcriptase PCR (qRT-PCR) assay. This webinar will discuss background, technique, reagents and instrumentation used in wastewater testing as it applies to SARS-CoV-2 research, as well as implications for analysis of other pathogens and infectious diseases.

Disclaimer: Agilent products are NOT approved for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.

Sponsored by

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.